Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% ...

JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Longer Term Trading Plans for ATXS. Buy ATXS near 7.19 target 9.02 stop loss @ 7.17 Details; The technical summary data tells us to buy ATXS near 7.19 with an upside target of 9.0 ...

LifeSprout, a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced it has filed for CE Mark registration for ...

The Global Genes Corporate Alliance, an initiative that brings together biopharmaceutical companies and academic institutions working to improve access and treatments for people with rare diseases, ...

According to a recent press release from Astria Therapeutics, the trial is anticipated to be initiated in the first quarter of 2025. Top-line results from ALPHA-ORBIT are expected in early 2027. The ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...